Lung Cancer Therapeutics Market size

According to the report by Expert Market Research (EMR), the global lung cancer therapeutics market size, reached a value of USD 31.6 billion in 2022. Aided by the growing prevalence of lung cancer and the continuous advancements in therapeutic options, the market is projected to further grow at a CAGR of 11.60% between 2023 and 2031 to reach a value of USD 76.9 billion by 2031.

Lung cancer therapeutic drugs include chemotherapies, targeted therapies, and immunotherapies, which play a crucial role in the treatment and management of lung cancer. These therapeutic approaches serve as lifelines, extending and improving the quality of life for many patients. They are designed to eradicate or control cancer cells, preventing them from spreading and causing further damage.

Get a Free Sample Report with Table of Contents –

The escalating global prevalence of lung cancer is significantly contributing to the expansion of the lung cancer therapeutics market growth. With the growing awareness about the detrimental health effects of tobacco use, occupational hazards, and air pollution, there has been a discernible rise in lung cancer cases, driving the need for effective therapeutics. Moreover, the ageing global population, which is more susceptible to such chronic diseases, is also pushing up the demand for lung cancer therapeutic drugs.

The broadening applications of lung cancer therapeutics in healthcare also propel the lung cancer therapeutics market expansion. In the pharmaceutical industry, newer, more effective drugs are continually being developed and tested. Chemotherapies have long been used to treat lung cancer, but targeted therapies and immunotherapies are emerging as vital components of personalised treatment plans, contributing significantly to market growth.

Moreover, lung cancer therapeutics are vital in palliative care, where they are used to manage symptoms and improve the quality of life for patients with advanced cancer. Innovative therapies are also being explored for their potential in preventing lung cancer in high-risk individuals, offering another avenue for market growth.

Furthermore, the growing focus on the development of targeted therapies and immunotherapies is bolstering the lung cancer therapeutics market expansion. With the rise in precision medicine and the increasing understanding of the molecular mechanisms of cancer, there has been an accelerated development of targeted therapies and immunotherapies. These offer more precise and personalised treatment options, often with fewer side effects, thereby enhancing their acceptance among patients and healthcare professionals alike.

In addition, advancements in the field of lung cancer research and the entry of promising therapeutic candidates into clinical trials are key factors driving market growth. These advances promise improved survival rates and better quality of life for patients, further amplifying the lung cancer therapeutics market demand.

Lung Cancer Therapeutics Market Segmentation

The market can be divided based on cancer type, therapy, therapy type, end user, distribution channel, and region.

Market Breakup by Cancer Type

• Non-Small Cell Lung Cancer
• Small Cell Lung Cancer (SCLC)
• Metastatic Lung Cancer
• Mesothelioma
• Others

Market Breakup by Therapy

• Chemotherapy
• Immunotherapy
• Radiation Therapy
• Targeted Therapy
• Others

Market Breakup by Therapy Type

• Single Drug Therapy
• Combination Therapy

Market Breakup by End User

• Hospitals
• Homecare
• Speciality Clinics
• Others

Market Breakup by Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

Market Breakup by Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa

Competitive Landscape

The EMR report looks into the market shares, plant turnarounds, capacities, investments, and acquisitions and mergers, among other major developments, of the global lung cancer
therapeutics companies. Some of the major key players explored in the report by Expert Market Research are as follows:

• Genentech, Inc.
• AstraZeneca PLC
• Novartis AG
• Merck KGaA
• F. Hoffmann-La Roche Ltd
• Boehringer Ingelheim International GmbH
• Agennix AG
• Eli Lilly and Company
• Sanofi-Aventis
• GlaxoSmithKline
• Hoffman-La Roche

About Us

Acquire unparalleled access to critical industry insights with our comprehensive market research reports, meticulously prepared by a team of seasoned experts. These reports are designed to equip decision-makers with an in-depth understanding of prevailing market trends, competitive landscapes, and growth opportunities.

Our high-quality, data-driven analyses provide the essential framework for organisations seeking to make informed and strategic decisions in an increasingly complex and rapidly evolving business environment. By investing in our market research reports, you can ensure your organisation remains agile, proactive, and poised for success in today’s competitive market.

Don’t miss the opportunity to elevate your business intelligence and fortify your strategic planning. Secure your organisation’s future success by acquiring one of our Expert Market Research reports today.

Media Contact:

Company Name: Claight Corporation
Contact Person: Jhon Roy, Business Consultant
Toll Free Number: US +1-415-325-5166 | UK +44-702-402-5790
Address: 30 North Gould Street, Sheridan, WY 82801, USA

View your news on Google News or contact our team